已上市与2005-2016年FDA新批药物的理化性质、生物转化与转运途径系统综述
该研究基于华盛顿大学药物相互作用数据库等资源,比较前200种最常处方药物(已上市)与2005-2016年FDA新批药物的给药途径、理化性质、前药及代谢酶/转运体贡献。结果显示新批药物中生物制品占比更高、亲脂性化合物增多,CYP3A4贡献从40%升至64%,OATP1B1和P-gp分别为主要摄取和外排转运体。
要点
- 新批药物中生物制品占比是已上市药物的15倍,反映蛋白和抗体疗法需求增长。
- CYP3A4作为主要代谢途径的贡献从已上市药物的40%升至新批药物的64%。
- OATP1B1和P-gp分别是贡献最大的摄取和外排转运体。
核心结论
- 新批药物中生物制品占比更高,反映蛋白和抗体疗法需求增长。
- 新批药物中亲水性药物更多,提示毒性概率可能降低。
- CYP3A4贡献从40%升至64%,CYP1A2、CYP2C19和CYP2D6贡献下降。
- OATP1B1和P-gp分别作为主要摄取和外排转运体,贡献未显著变化。
研究设计与样本
- 系统综述,使用华盛顿大学药物相互作用数据库(DIDB®)及其他在线资源收集数据。
- 比较前200种最常处方药物(已上市)与2005-2016年FDA新批药物。
主要发现
- 约90%的已上市和新批药物通过全身途径(口服或静脉)给药。
- 新批药物中生物制品(分子量>1 kDa)占比是已上市药物的15倍。
- 新批药物中cLogP>3且总极性表面积>75 Å2的化合物数量增加4.5倍。
- 前药通过水解、去甲基酶和激酶转化为活性化合物。
- CYP3A4贡献从已上市药物的40%升至新批药物的64%。
关键数值与推荐
- 生物制品定义为分子量>1 kDa。
- 高脂溶性定义为计算分配系数cLogP>3。
- 高总极性表面积定义为>75 Å2。
临床怎么用
- 临床用药时应关注新批药物中生物制品和亲脂性药物增多的趋势。
- CYP3A4介导的代谢贡献增加,提示药物相互作用风险评估需重点关注CYP3A4。
- OATP1B1和P-gp作为主要转运体,其底物药物的转运相关相互作用仍需关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enzyme-mediated biotransformation of pharmacological agents is a crucial step in xenobiotic detoxification and drug disposition. Herein, we investigated the metabolism and physicochemical properties of the top 200 most prescribed drugs (established) as well as drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2016 (newly approved). OBJECTIVE: Our objective was to capture the changing trends in the routes of administration, physicochemical properties, and prodrug medications, as well as the contributions of drug-metabolizing enzymes and transporters to drug clearance. METHODS: The University of Washington Drug Interaction Database (DIDB®) as well as other online resources (e.g., CenterWatch.com, Drugs.com, DrugBank.ca, and PubChem.ncbi.nlm.nih.gov) was used to collect and stratify the dataset required for exploring the above-mentioned trends. RESULTS: Analyses revealed that ~ 90% of all drugs in the established and newly approved drug lists were administered systemically (oral or intravenous). Meanwhile, the portion of biologics (molecular weight > 1 kDa) was 15 times greater in the newly approved list than established drugs. Additionally, there was a 4.5-fold increase in the number of compounds with a high calculated partition coefficient (cLogP > 3) and a high total polar surface area (> 75 Å2) in the newly approved drug vs. the established category. Further, prodrugs in established or newly approved lists were found to be converted to active compounds via hydrolysis, demethylases, and kinases. The contribution of cytochrome P450 (CYP) 3A4, as the major biotransformation pathway, has increased from 40% in the established drug list to 64% in the newly approved drug list. Moreover, the role of CYP1A2, CYP2C19, and CYP2D6 were decreased as major metabolizing enzymes among the newly approved medications. Among non-CYP major metabolizers, the contribution of alcohol dehydrogenases/aldehyde dehydrogenases (ADH/ALDH) and sulfotransferases decreased in the newly approved drugs compared with the established list. Furthermore, the highest contribution among uptake and efflux transporters was found for Organic Anion Transporting Polypeptide 1B1 (OATP1B1) and P-glycoprotein (P-gp), respectively. CONCLUSIONS: The higher portion of biologics in the newly approved drugs compared with the established list confirmed the growing demands for protein- and antibody-based therapies. Moreover, the larger number of hydrophilic drugs found in the newly approved list suggests that the probability of toxicity is likely to decrease. With regard to CYP-mediated major metabolism, CYP3A5 showed an increased involvement owing to the identification of unique probe substrates to differentiate CYP3As. Furthermore, the contribution of OATP1B1 and P-gp did not show a significant shift in the newly approved drugs as compared to the established list because of their broad substrate specificity.
引用
- Saravanakumar A, Sadighi A, Ryu R, et al. Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. Clin Pharmacokinet. 2019. PMID: 30972694. doi:10.1007/s40262-019-00750-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。